Medivir | Jotup

Medivir to present at the Carlsquare Equity Research Investor Day

Retrieved on:

Wednesday, December 6, 2023

Nasdaq Stockholm, Drug development, Patient, Partnership, Market capitalization, Cancer, SMAC, Medivir

STOCKHOLM, Dec. 6, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, today December 6, 2023.

Key Points:

STOCKHOLM, Dec. 6, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, today December 6, 2023.
CEO Jens Lindberg will present at 14.30 CET, with focus on the latest developments and the company's future plans.
Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Retrieved on:

Monday, November 27, 2023

Quotient, Trial of the century, Liver cancer, HCC, Safety, Patient, Medivir, Cancer, Pharmaceutical industry, Lenvatinib

The need for new treatments is high and the development of an updated commercial formulation is an additional step towards fostrox becoming a treatment option for HCC patients.

Key Points:

The need for new treatments is high and the development of an updated commercial formulation is an additional step towards fostrox becoming a treatment option for HCC patients.
The development efforts have been carried out by Quotient Sciences, Medivir's partner for formulation development and manufacture of drug product.
A formulation suitable for commercial manufacture is a critical component in clinical studies with regulatory intent.
- "With the plans to initiate a phase 2b study with registrational intent, it is imperative that we use the formulation intended for commercial launch in the study.

Medivir to present at the Redeye Life Science Day

Retrieved on:

Wednesday, November 22, 2023

Nasdaq Stockholm, Drug development, CET, Patient, Partnership, Market capitalization, Cancer, Red eye, SMAC, Pharmaceutical industry, Medivir

STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Life Science Day, tomorrow November 23, 2023.

Key Points:

STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Life Science Day, tomorrow November 23, 2023.
CEO Jens Lindberg will participate in an In Focus interview at 13.20 CET, led by Redeye analyst Richard Ramanius, with focus on the latest developments and the company's future plans.
Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

Constructive Bio Strengthens Management Team and Board of Directors with Key Appointments to Accelerate Synthetic Genomics to Innovate Biologic Therapies

Retrieved on:

Thursday, November 2, 2023

He has executed some of the industry’s most impactful strategic transactions with major pharma, regularly at the leading edge of deal trends.

Key Points:

He has executed some of the industry’s most impactful strategic transactions with major pharma, regularly at the leading edge of deal trends.
His proven track record of success includes out-licensing the hepatitis C protease inhibitor Olysio®, one of the fastest-launched drugs in the history of the industry.
Paul joins Constructive Bio to accelerate the commercialisation and strategic partnering of its ground-breaking genetic code reprogramming platform.
The synthetic genome platform at Constructive Bio is a powerful tool that will change the way we imagine biology, including the breakthrough therapies we need to improve global health.“
For further information please contact:

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Retrieved on:

Wednesday, October 25, 2023

HCC, CSO, Conference, Magnus Christensen, Webcast, Conference call, CET, CFO, Medivir, Cancer, CMO, Patient, Defence Scientific Advisory Council, Pharmaceutical industry, Broadcasting

STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today the company plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma (HCC). The data will focus on the 18 out of 21 total patients that have had a minimum follow-up of 12 weeks.

Key Points:

The data will focus on the 18 out of 21 total patients that have had a minimum follow-up of 12 weeks.
All presenters will be available to answer questions following the formal presentations.
To access the webcast and information about the teleconference, please click HERE !
The webcast will also be streamed via a link on the website: www.medivir.com/investors/calendar
The presentation will be available on Medivir's website after the webcast.

Nomination Committee of Medivir appointed

Retrieved on:

Monday, October 23, 2023

Medivir, AGM, Annual, Committee, Lumber

STOCKHOLM, Oct. 23, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2024.

Key Points:

STOCKHOLM, Oct. 23, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2024.
According to an AGM resolution, the Nomination Committee 2023-2024 should consist of representatives of at least the three largest shareholders at the end of the third quarter of 2023 and the Chairman of the Board.
Work on composing the Nomination Committee is now completed, and this year's Nomination Committee consists of:
The 2024 Annual General Meeting of Medivir will be held on Tuesday May 7, 2024.

Change in Medivir's Board of Directors

Retrieved on:

Friday, October 20, 2023

Cancer, Management, Medivir

STOCKHOLM, Oct. 20, 2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) and (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company's board member Anette Lindqvist has informed the board of directors that she is leaving her position due to personal reasons.

Key Points:

STOCKHOLM, Oct. 20, 2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) and (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company's board member Anette Lindqvist has informed the board of directors that she is leaving her position due to personal reasons.
"We respect Anette's decision and at the same time want to thank her for her meritorious efforts.
With her competence and experience, she has been a valuable force in the board's work," says Uli Hacksell, chairman of Medivir's board of directors.
Medivir's nomination committee has initiated the search for a replacement for Anette Lindqvist.

Medivir to present at the Pareto Securities Healthcare Conference

Retrieved on:

Thursday, September 14, 2023

Cancer, Partnership, Drug development, Market capitalization, Patient, Nasdaq Stockholm, Conference, SMAC, Medivir, Pharmaceutical industry

STOCKHOLM, Sweden , Sept. 14, 2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Pareto Securities Healthcare Conference, Today, September 14, at 12.55 CET.

Key Points:

STOCKHOLM, Sweden , Sept. 14, 2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Pareto Securities Healthcare Conference, Today, September 14, at 12.55 CET.
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high.
Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

Retrieved on:

Monday, September 11, 2023

Cancer, HRD, Breast, USP1, Investigational New Drug, Prostate cancer, Patient, FDA, Therapy, PARP, Pharmaceutical industry, Medivir

TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers.

Key Points:

TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers.
HRD+ cancers, including BRCA1/2 mutations, represent up to 50% of ovarian cancers, 25% of breast cancers, 10% of prostate cancers and 5% of pancreatic cancers.
Tango Therapeutics intends to initiate a phase 1 / 2 study with TNG348 in first half of 2024, both as single agent and in combination with a PARP-inhibitor.
The preclinical data generated by Tango Therapeutics looks very promising and we will be following the clinical development of TNG348 with great anticipation," says Jens Lindberg, CEO of Medivir.

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Retrieved on:

Friday, September 1, 2023

The webcast will feature presentations by Dr. Jeff Evans, Beatson West of Scotland Cancer Center, Glasgow, UK, who will discuss the current treatment landscape and unmet medical need in treating patients with HCC.

Key Points:

The webcast will feature presentations by Dr. Jeff Evans, Beatson West of Scotland Cancer Center, Glasgow, UK, who will discuss the current treatment landscape and unmet medical need in treating patients with HCC.
He will be joined by Dr. Maria Reig, Liver Cancer Unit, Hospital Clínic BCLC group, Villarroel, Barcelona, Spain, who will discuss how HCC is different from many other tumor types and its unique treatment challenges.
Both Drs are investigators in the phase 1b/2a study with fostrox in combination with Lenvima and will also share their perspectives from the ongoing study.
The webcast will be streamed via a link on the website: www.medivir.com/investors/presentations The presentation will be available on Medivir´s website after the webcast.